Veronika Reidel und Bcl-2 - Info zur Person

Prof. (SHB) Dr. med. Dirk Hempel - Facharztzentrum ...

www.facharztzentrum-ffb.com

Selective inhibition of BCL-2 is a promising target in patients with high-risk Myelodysplastic Syndrome and adverse mutational profile. Veronika Reidel 1, Johanna Kauschinger 1, Richard Tilmann Hauch 1, Catharina Müller-Thomas 1, Niroshan Nadarajah 2, Rainer Burgkart 3, Burkhard Schmidt 4, Dirk Hempel 5, Anne Jacob 1, Julia Slotta-Huspenina 6, Ulrike Höckendorf 1, Christian Peschel 1,7 ...

Protein levels of BCL-2, BCL-XL and MCL-1 predict resistance to pro ...ur.booksc.me › book

ur.booksc.me

... Veronika Reidel, Catharina Müller-Thomas, Höckendorf Ulrike, Christian Peschal, A. Oostendorp Robert, Katharina S. Götze, Phillip J. Jost Technische ...

Veröffentlichungen von Prof. (SHB) Dr. med. …

www.cancer-center.eu

Selective inhibition of BCL-2 is a promising target in patients with high-risk Myelodysplastic Syndrome and adverse mutational profile. Veronika Reidel 1, Johanna Kauschinger 1, Richard Tilmann Hauch 1, Catharina Müller-Thomas 1, Niroshan Nadarajah 2, Rainer Burgkart 3, Burkhard Schmidt 4, Dirk Hempel 5, Anne Jacob 1, Julia Slotta-Huspenina 6, Ulrike Höckendorf 1, Christian Peschel 1,7 ...

Veronika Reidel und Bcl-2 Person-Info

Prof. (SHB) Dr. med. Dirk Hempel - Facharztzentrum ...

Protein levels of BCL-2, BCL-XL and MCL-1 predict resistance to pro ...ur.booksc.me › book

Alle Infos zum Namen "Veronika Reidel"

Veröffentlichungen von Prof. (SHB) Dr. med. …

Protein levels of BCL-2, BCL-XL and MCL-1 predict resistance to...

Selective inhibition of BCL-2 is a promising target in patients with...

Selective inhibition of BCL-2 is a promising target in Oncotargetwww.oncotarget.com › article › text